SCHEMBL19679883

SCHEMBL19679883

O=c1cc(O)cc(CCc2ccc(O)c(O)c2)o1

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALOX15 P16050 5/20 0.47
IGF1R P08069 3/20 0.47
CYP19A1 P11511 1/20 0.46
TYR P14679 1/20 0.46
LCK P06239 1/20 0.46
KDM4E B2RXH2 4/20 0.46
MAPT P10636 4/20 0.46
ALDH1A1 P00352 3/20 0.46
GAA P10253 2/20 0.46
ALOX5 P09917 1/20 0.46
BACE1 P56817 1/20 0.46
RECQL P46063 3/20 0.45
TDP1 Q9NUW8 3/20 0.45
MAPK1 P28482 3/20 0.45
APEX1 P27695 2/20 0.45
THPO P40225 2/20 0.45
HIF1A Q16665 2/20 0.45
HSD17B10 Q99714 2/20 0.45
LMNA P02545 2/20 0.45
BLM P54132 2/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21317639 0.85 HTR2B (0.54) CYP19A1KDM4EMAPTALDH1A1GAA
SCHEMBL19665514 0.81 AKR1B1 (0.61) ALOX15IGF1RLCKAKR1B1HTR2B
SCHEMBL6174381 0.80 HTR2B (0.54) MAPTGAAHTR2B
SCHEMBL7959794 0.78 CALM1 (0.57) ALDH1A1CYP3A4TAAR1
SCHEMBL18417920 0.77 HTR2B (0.60) ALOX15CYP19A1TYRKDM4EMAPT
SCHEMBL30631592 0.74 ALOX15 (0.80) ALOX15IGF1RLCKKDM4EMAPT
SCHEMBL107956 0.74 ALOX15 (0.80) ALOX15IGF1RLCKKDM4EMAPT
SCHEMBL31733931 0.73 CYP3A4 (0.47) ALOX15KDM4EMAPTALDH1A1GAA
SCHEMBL4542482 0.73 ALOX15 (0.64) ALOX15IGF1RCYP19A1TYRLCK
SCHEMBL8431254 0.72 ALOX15 (0.76) ALOX15IGF1RLCKKDM4EMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20170349548-A1 P21-ACTIVATED KINASE INHIBITOR BIOSYSTEM CONSULTING LIMITED COMPANY (JP) 2017-12-07 US disclosed
US-20170349548-A1 P21-ACTIVATED KINASE INHIBITOR BIOSYSTEM CONSULTING LIMITED COMPANY (JP) 2017-12-07 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170349548-A1 P21-ACTIVATED KINASE INHIBITOR HIPK1, CDKN1A, HIPK2 ALOX15 3381/4885IGF1R 1083/4885CYP19A1 2394/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.